Cue Biopharma (NASDAQ:CUE) Rating Reiterated by Oppenheimer
Cue Biopharma (NASDAQ:CUE – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. Oppenheimer’s target price suggests a potential upside of 390.20% from the company’s current price. Several other research […]